M. Vianello

发表

Humoral autoimmune responses to glutamic acid decarboxylase have similar target epitopes and subclass that show titer-dependent disease association.

E. Bonifacio, B. Giometto, S. Piquer, 2005, Clinical immunology.

PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study

G. Marfia, M. Rovaris, M. Filippi, 2021, Journal of Neurology.

Risk of Getting COVID-19 in People With Multiple Sclerosis

M. Filippi, G. Tedeschi, G. Comi, 2022, Neurology: Neuroimmunology & Neuroinflammation.

Do patients’ and referral centers’ characteristics influence multiple sclerosis phenotypes? Results from the Italian multiple sclerosis and related disorders register

M. Ulivelli, G. Marfia, M. Rovaris, 2022, Neurological Sciences.

Glutamic acid decarboxylase autoantibodies and neurological disorders

B. Giometto, B. Tavolato, M. Vianello, 2002, Neurological Sciences.

Towards a validated definition of the clinical transition to secondary progressive multiple sclerosis: A study from the Italian MS Register

M. Filippi, C. Pozzilli, M. Onofrj, 2022, Multiple sclerosis.

Post-marketing of disease modifying drugs in multiple sclerosis: An exploratory analysis of gender effect in interferon beta treatment

C. Pozzilli, G. Comi, M. Trojano, 2009, Journal of the Neurological Sciences.

CHAPTER 68 – Paraneoplastic Neurologic Diseases: Autoimmune Responses to Tumor Antigens

B. Giometto, M. Vianello, R. Vitaliani, 2006 .

Immunological Mechanisms of Paraneoplastic Nervous System Diseases

B. Giometto, T. Scaravilli, B. Tavolato, 2002 .

Disease-Modifying Treatments and Time to Loss of Ambulatory Function in Patients With Primary Progressive Multiple Sclerosis.

M. Filippi, C. Pozzilli, G. Comi, 2022, JAMA neurology.

Increased spontaneous activity of a network of hippocampal neurons in culture caused by suppression of inhibitory potentials mediated by anti-gad antibodies

M. dal Maschio, Giacomo Bisson, B. Giometto, 2008, Autoimmunity.

Cerebellar ataxia associated with anti-glutamic acid decarboxylase autoantibodies

B. Giometto, B. Tavolato, M. Armani, 2008, The Cerebellum.

The impact of PM2.5, PM10 and NO2 on Covid-19 severity in a sample of patients with multiple sclerosis: A case-control study

G. Marfia, M. Rovaris, M. Filippi, 2022, Multiple Sclerosis and Related Disorders.

Do patients’ and referral centers’ characteristics influence multiple sclerosis phenotypes? Results from the Italian multiple sclerosis and related disorders register

M. Ulivelli, G. Marfia, M. Rovaris, 2022, Neurological Sciences.

X‐linked adrenoleukodystrophy with olivopontocerebellar atrophy

B. Giometto, B. Tavolato, R. Manara, 2005, European journal of neurology.

The spectrum of antineuronal autoantibodies in a series of neurological patients

F. Scaravilli, B. Giometto, B. Tavolato, 2004, Journal of the Neurological Sciences.

Antigenic differences between neurological and diabetic patients with anti‐glutamic acid decarboxylase antibodies

B. Giometto, B. Tavolato, E. Thompson, 2005, European journal of neurology.

Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register

M. Filippi, M. Onofrj, M. Trojano, 2021, Neurotherapeutics.

Multiple cranial nerve involvement in Bannwarth’s syndrome

B. Giometto, G. Marchiori, M. Vianello, 2008, Neurological Sciences.

Tremor of the mouth floor and anti‐glutamic acid decarboxylase autoantibodies

B. Giometto, T. Scaravilli, B. Tavolato, 2003, European journal of neurology.

Real‐life impact of early interferonβ therapy in relapsing multiple sclerosis

C. Pozzilli, G. Comi, M. Trojano, 2009, Annals of neurology.

Peculiar labeling of cultured hippocampal neurons by different sera harboring anti-glutamic acid decarboxylase autoantibodies (GAD-Ab)

B. Giometto, S. Vassanelli, M. Canato, 2006, Experimental Neurology.

Encephalitis associated with glutamic acid decarboxylase autoantibodies

B. Giometto, P. Bardin, G. Marchiori, 2001, Neurology.

Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis.

C. Pozzilli, G. Comi, M. Trojano, 2020, Brain : a journal of neurology.

Comparing Natural History of Early and Late Onset Pediatric Multiple Sclerosis

M. Rovaris, M. Filippi, M. Onofrj, 2022, Annals of neurology.

Clinical, immunological and therapeutic aspects of autoimmune encephalitis.

B. Giometto, M. Vianello, R. Vitaliani, 2008, Recent Patents on CNS Drug Discovery.

Patient satisfaction with televisit in chronic neurologic disorders during Covid-19 pandemic

D. Bonifati, I. Rosellini, S. Guidoni, 2023, Acta Neurologica Belgica.

Virtual visits for chronic neurologic disorders during COVID-19 pandemic

D. Bonifati, A. Ghazaryan, I. Rosellini, 2021, Neurological Sciences.

Patient satisfaction with televisit in chronic neurologic disorders during COVID-19 pandemic

D. Bonifati, A. Ghazaryan, I. Rosellini, 2021, Journal of the Neurological Sciences.

Data monitoring roadmap. The experience of the Italian Multiple Sclerosis and Related Disorders Register

M. Ulivelli, G. Comi, M. Trojano, 2023, Neurological Sciences.

Changing therapeutic strategies and persistence to disease-modifying treatments in a population of multiple sclerosis patients from Veneto region, Italy.

M. Benedetti, F. Marchioretto, F. Rossi, 2020, Multiple sclerosis and related disorders.

Post-marketing of disease modifying drugs in multiple sclerosis: An exploratory analysis of gender effect in interferon beta treatment

C. Pozzilli, G. Comi, M. Trojano, 2009, Journal of the Neurological Sciences.

A comparison of natalizumab and ocrelizumab on disease progression in multiple sclerosis.

G. Marfia, M. Trojano, F. Granella, 2024, Annals of clinical and translational neurology.